# Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

> **NCT03910387** · PHASE2 · COMPLETED · sponsor: **Emory University** · enrollment: 23 (actual)

## Conditions studied

- Locally Advanced Unresectable Pancreatic Adenocarcinoma
- Metastatic Pancreatic Adenocarcinoma
- Recurrent Pancreatic Adenocarcinoma
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel
- **DRUG:** Telotristat Ethyl

## Key facts

- **NCT ID:** NCT03910387
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-17
- **Primary completion:** 2022-06-29
- **Final completion:** 2022-06-29
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-12-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03910387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03910387, "Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT03910387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*